Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (PERMICA)

Last updated: February 12, 2025
Sponsor: Poitiers University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Collection of biological samples and clinical data

Clinical Study ID

NCT06809660
2024-A02197-40
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Colorectal cancer is the third most common cancer worldwide, yet it was the second leading cause of cancer-related deaths in 2020. The average French population faces a colorectal cancer risk partly linked to lifestyle factors. The majority of colorectal cancer cases (approximately 85%) are not caused by hereditary mutations. Environmental factors, such as lifestyle or diet (notably through endocrine disruptors), can affect the gut microbiota (a collection of microorganisms - bacteria, viruses, parasites, and fungi

  • residing in the intestinal environment) and lead to disturbances in its composition, referred to as dysbiosis. While the mechanisms underlying dysbiosis associated with colorectal cancer remain poorly understood, the involvement of certain ingested substances, known as xenobiotics, is increasingly suspected, including endocrine disruptors. Among the most common endocrine disruptors found in water and food are parabens and phthalates, which will be examined in detail in this study. These substances may be directly involved in the development of colorectal cancer and in response to its treatment.

The main objective of this studie is to characterize the relationship between colorectal cancer diagnosis, activity/composition of the gut microbiota, and patients' exposure to selected endocrine disruptors, particularly parabens and phthalates.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Scheduled endoscopy during the inclusion visit or within 18 months following thisconsultation.

  • Signed consent from the patient after clear and fair information about the study isprovided.

  • Patient is free of guardianship, curatorship, or dependency.

  • Patient is covered by a social security system or through a third party.

Exclusion

Exclusion Criteria:

  • Patients receiving treatment for chronic inflammatory bowel disease;

  • Patients with hereditary colorectal cancer;

  • Use of antibiotics, probiotics, or prebiotics within four weeks prior to stoolsample collection;

  • Patients who have undergone neoadjuvant chemotherapy or radiotherapy;

  • Patients who have had previous surgical resection;

  • Patients under enhanced protection: minors, individuals deprived of liberty byjudicial or administrative decision, individuals residing in healthcare or socialinstitutions, and adults under legal protection;

  • Pregnant and/or breastfeeding women.

Exclusion Criteria During Study Participation:

  • Patients presenting any of the following during their participation in the studywill be excluded:

  • Use of antibiotics, probiotics, or prebiotics before stool collection (betweeninclusion and stool collection, which may occur within the month);

  • Endoscopy not performed within 18 months following inclusion;

  • Failure to send/receive stool samples

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Collection of biological samples and clinical data
Phase:
Study Start date:
January 21, 2025
Estimated Completion Date:
January 21, 2034

Study Description

Methodology:

Pilot, single-center regional study, with a descriptive and comparative design (patients with colorectal cancer / patients without suspected colorectal cancer = controls).

In each group, a stool, hair and urine sample will be collected and an endocrine disruptor exposure questionnaire completed.

Sample Size and Duration:

A total of 200 patients will be included, divided into two groups of 100 patients (100 patients with colorectal cancer and 100 patients without suspected colorectal cancer). The inclusion period will last 48 months, with each participant enrolled for a maximum of one month. Routine care data will be collected over 5 years. The total duration of the clinical investigation will be approximately 9 years.

Expected Outcomes:

The investigators aim at determining whether the most common endocrine disruptors in the French population are involved in colorectal carcinogenesis and if these substances are correlated with dysbiotic colorectal microbiota.

The findings from this study should help identify the endocrine disruptors most frequently associated with colorectal cancer and thereby enhance vigilance regarding these substances.

Benefits for Patients:

There are no individual but collective benefits, as the results will colorectal cancer related knowledge and its relationship with lifestyle.

Connect with a study center

  • CHU de Poitiers

    Poitiers, 86000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.